Ameren Announces Pricing of Senior Notes due 2036 [Accessibility Statement] Skip NavigationST. LOUIS, Feb. 26, 2026 /PRNewswire/ -- Ameren Corporation (NYSE: AEE) announced today the pricing of a public offering of $400 million aggregate principal amount of 5.00% senior notes due 2036 at 99.802% of their principal amount. The transaction is expected to close on March 4, 2026, subject to the satisfaction of customary closing conditions.Ameren intends to use the net proceeds of the offering for general corpor ...

W. P. Carey Announces Full Exercise of Underwriters' Option to Purchase Additional Shares [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- W. P. Carey Inc. (NYSE: WPC, the "Company") announced today that the underwriters of its previously closed and announced underwritten public offering of an aggregate of 6,000,000 shares of common stock, offered on a forward basis, have exercised in full their option to purchase an additional 900,000 shares of the Company's common stock. Th ...

Energy Services of America Corporation Announces Closing of Overallotment Option and Issuance of 261,000 Shares of Common Stock [Accessibility Statement] Skip NavigationHUNTINGTON, W.Va., Feb. 24, 2026 /PRNewswire/ -- Energy Services of America Corporation (the "Company"), today announced that the underwriter for its recently completed public offering has exercised its overallotment option and completed the sale of an additional 261,000 shares of common stock at the public offering price of $11.50 per share ...

Cooper Standard Announces Pricing of $1.1 Billion of Senior Secured First Lien Notes [Accessibility Statement] Skip NavigationNORTHVILLE, Mich., Feb. 20, 2026 /PRNewswire/ -- Cooper-Standard Holdings Inc. (NYSE: CPS) ("Cooper Standard," "Company" or "we") today announced the pricing of the private offering by its wholly-owned subsidiary, Cooper-Standard Automotive Inc. (the "Issuer"), of $1,100.0 million in aggregate principal amount of 9.250% Senior Secured First Lien Notes due 2031 (the "Notes"). The Note ...

Core Viewpoint - Marimaca Copper Corp. is conducting a treasury offering of approximately C$136 million (~ A$141 million) and a secondary offering of approximately C$273 million (~ A$283 million) to fund its Marimaca Project and provide liquidity to selling shareholders [1][2][4]. Offering Details - The Canadian Offering will be priced at C$10.00 per Common Share and is expected to close around February 26, 2026, pending regulatory approvals [2]. - The Australian Offering will involve a brokered placement of CHESS Depositary Interests (CDIs) at A$10.35 per CDI, also expected to close around February 26, 2026 [3]. Use of Proceeds - Net proceeds from the treasury offering will be allocated to advance the Marimaca Project, including pre-construction engineering, early site works, and a drilling campaign at Pampa Medina, along with working capital and general corporate purposes [4]. Shareholder Agreements - Selling shareholders have agreed not to sell any Common Shares or CDIs for a 90-day period following the Global Offering, subject to certain exceptions [5]. Regulatory Compliance - The Canadian Offering will be made via a prospectus supplement to the Company's base shelf prospectus and may be offered in the U.S. to qualified institutional buyers under the U.S. Securities Act [6][8]. - The CDIs will be offered in Australia to professional investors and in other jurisdictions to institutional or sophisticated investors [7]. Company Overview - Marimaca Copper Corp. is focused on its 100%-owned Marimaca Copper Project located in the Antofagasta Region of Chile, which hosts the Marimaca Oxide Deposit [10][11]. - The Company is progressing through detailed engineering and permitting processes while exploring its extensive land package in the region [11].

WASHINGTON, D.C. 20549 As filed with the Securities and Exchange Commission on February 13, 2026. Registration No. 333-293204 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Amendment No. 1 THE SECURITIES ACT OF 1933 Generate Biomedicines, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 83-1630228 (Primary Standard Industrial Classification Code Number) 101 South Street, Suite 900 Somerville, MA 02143 (I.R.S. Employer ...

Core Insights - Nektar Therapeutics has successfully closed a public offering of $460 million, which includes the full exercise of underwriters' option to purchase additional shares [1] Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing innovative medicines in immunotherapy [1] - The company's lead product candidate is rezpegaldesleukin (REZPEG or NKTR-358), which is being evaluated in multiple Phase 2 clinical trials for atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus [1] - Nektar's pipeline includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422 [1] - The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist, in several ongoing clinical trials aimed at enhancing the immune system's ability to combat cancer [1] Offering Details - The offering consisted of 7,637,931 shares of common stock sold at a public offering price of $58.00 per share, along with 293,103 pre-funded warrants sold at $57.9999 each [1] - Gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions [1] - Jefferies, TD Cowen, and Piper Sandler acted as joint bookrunning managers for the offering, with Oppenheimer & Co. and H.C. Wainwright & Co. as lead managers [1]

Core Viewpoint - W. P. Carey Inc. has successfully priced a public offering of €1.0 billion in senior unsecured notes, with a weighted-average coupon of 3.500% and a term of 7.4 years, aimed at refinancing existing debt and supporting general corporate purposes [1] Group 1: Offering Details - The offering consists of two tranches: €500 million of 3.750% Senior Notes due 2035, priced at 98.500% of the principal amount, and €500 million of 3.250% Senior Notes due 2031, priced at 99.249% of the principal amount [1] - Interest payments for the 2031 Notes will commence on October 2, 2026, while the 2035 Notes will start on May 10, 2026 [1] - The settlement of the offering is expected on February 24, 2026, subject to customary closing conditions [1] Group 2: Use of Proceeds - The net proceeds from the offering will be used to repay €500 million of 2.250% Senior Notes due April 2026 and for general corporate purposes, including funding potential future investments and repaying other indebtedness [1] Group 3: Management and Regulatory Information - J.P. Morgan Securities plc, Barclays Bank PLC, BNP PARIBAS, and Wells Fargo Securities International Limited are acting as joint book-running managers for the offering [1] - A registration statement for the Notes has been filed with the SEC and has become effective under the Securities Act of 1933 [1]

Core Viewpoint - Royal Caribbean Group has announced the pricing of $1.25 billion in senior unsecured notes, with two tranches maturing in 2033 and 2038, aimed at refinancing existing debt and repaying other obligations [1][2] Group 1: Offering Details - The company priced $1.25 billion of 4.750% senior unsecured notes due May 15, 2033, and $1.25 billion of 5.250% senior unsecured notes due February 27, 2038 [1] - The expected issuance date for the notes is around February 27, 2026, pending customary closing conditions [1] - The offering is made under an automatic shelf registration statement filed with the SEC on February 29, 2024 [1] Group 2: Use of Proceeds - The net proceeds from the notes will be used to refinance senior notes maturing in 2026 and to repay existing indebtedness, which may include term loans [1] Group 3: Management and Structure - J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, and PNC Capital Markets LLC are the lead book-running managers for the offering [1] - Royal Caribbean Group operates 69 ships and offers vacation experiences across more than 1,000 destinations globally through its brands [2]

Contango Ore Closes $50 Million Underwritten Offering of Common Stock and Pre-funded Warrants [Accessibility Statement] Skip NavigationFAIRBANKS, Ala., Feb. 12, 2026 /PRNewswire/ - Contango ORE, Inc. ("Contango" or the "Company") (NYSE American: CTGO), is pleased to announce that it has closed its previously announced underwritten offering (the "Offering") of common stock (the "Shares") of the Company consisting of 1,678,206 Shares at an offering price of $24.96 per Share to two institutional investors. In ...